Kantonsspital St.Gallen

PhenoTox: Hunting the missing heritability of early-onset fluoropyrimdine-related toxicity in cancer patients: an observational multi-center study

Markus Joerger

Kurzfassung In cancer patients receiving fluoropyrimidine-based chemo-therapy, there is extensive inter-individual variability in plasma drug concentrations and the severity of chemo-therapy-related toxicity. A strong association has been shown for plasma concentrations and drug-related toxicity as well as clinical outcome in 5-fluorouracil treated cancer patients. In spite of the identification of some genetic risk factors that contribute to this inter-individual variability, a majority of toxicity occurrences remain unexplained. Cur-rently, variability in drug exposure related to BSA-based dosing hampers the identification of genetic factors con-tributing to individual FP toxicity risk and the quantification of their clinical relevance. Thus, the power of association studies can be improved by accounting for differences in individual drug exposure.
Art des Forschungsprojektes Klinische Forschung
Status Laufend - Rekrutierungsphase
Projektstart 2016
Projektende 2020
Verantwortliche Person / Hauptprüfarzt am KSSG PD Dr. med. Markus Jörger